Avivagen Inc. | Cash Flow

Fiscal year is November-October. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
2,024.00
2,080.40
2,015.00
2,744.00
5,135.70
4,834.10
Depreciation, Depletion & Amortization
68.20
33.10
20.80
11.70
-
2.50
Other Funds
73.20
133.00
207.80
-
-
1,258.70
Funds from Operations
1,353.70
1,787.70
1,795.60
2,380.30
4,596.90
3,572.80
Changes in Working Capital
1,299.30
19.50
153.70
196.00
175.80
236.60
Net Operating Cash Flow
2,653.10
1,768.30
1,641.80
2,184.30
4,772.70
3,809.40
Issuance/Reduction of Debt, Net
-
-
85.80
1,033.00
128.80
Net Financing Cash Flow
3,514.60
1,491.40
1,505.30
6,694.70
1,227.60
Net Change in Cash
861.50
276.90
136.50
4,510.20
3,542.30
Free Cash Flow
2,653.10
1,768.30
1,641.80
-
4,772.70
Change in Capital Stock
3,587.70
1,358.40
1,383.40
5,661.70
1,356.40
Exchange Rate Effect
-
-
-
0.20
2.90

About Avivagen

View Profile
Address
100 Sussex Drive
Ottawa Ontario K1A 0R6
Canada
Employees -
Website http://www.avivagen.com
Updated 07/08/2019
Avivagen, Inc. engages in the development and commercialization of products for livestock. Its products include OxC-beta Livestock, Vivamune Vital Health Chews and Oximunol Chewable Tablets. The company was founded by Janusz Daroszewsk and Graham W.